Streptococcus infections: Group B https://greenmedinfo.com/taxonomy/term/5598/all en A 39-year-old woman with rheumatoid arthritis developed intrapartum anaphylaxis that led to fetal demise. https://greenmedinfo.com/article/39-year-old-woman-rheumatoid-arthritis-developed-intrapartum-anaphylaxis-led-f PMID:  Ann Allergy Asthma Immunol. 2007 Sep;99(3):287-9. PMID: 17910335 Abstract Title:  Intrapartum anaphylaxis to penicillin in a woman with rheumatoid arthritis who had no prior penicillin allergy. Abstract:  BACKGROUND: Little is known about the development of drug allergy during pregnancy or in patients with altered immune status.OBJECTIVE: To report a case of new-onset penicillin allergy during pregnancy in a woman with rheumatoid arthritis.METHODS: A 39-year-old woman with rheumatoid arthritis developed intrapartum anaphylaxis that led to fetal demise. She had previously received penicillin-based antibiotics without any allergic reactions. Because of group B streptococcus colonization, an intravenous infusion of penicillin G was started during labor. Within minutes, she developed severe anaphylaxis.RESULTS: A fluorescent enzyme immunoassay revealed a moderate level of specific IgE to penicilloyl G and penicilloyl V (3.15 kU/L and 2.77 kU/L, respectively). Given the patient&#039;s history, these positive results were considered confirmatory of penicillin allergy. This case raises a number of salient points. First, patients can develop severe allergy to penicillin despite having safely received penicillins in the past. Possible factors that influenced the development of severe penicillin sensitivity in this patient are discussed. Second, unexpected intrapartum anaphylaxis can occur, which can be life threatening to the mother or fetus. Third, safe and reliable methods for diagnosis of drug allergy must be available.CONCLUSIONS: This case illustrates that during the current unavailability of skin testing reagents in the United States, a positive result on in vitro testing can be helpful in confirming penicillin allergy in cases in which drug challenge is deemed unsafe. https://greenmedinfo.com/article/39-year-old-woman-rheumatoid-arthritis-developed-intrapartum-anaphylaxis-led-f#comments Rheumatoid Arthritis Streptococcus infections: Group B Intrapartum Antibiotics: Group B Streptococcus Human: Case Report Thu, 24 Mar 2011 03:04:26 +0000 greenmedinfo 62839 at https://greenmedinfo.com All extracts and oil concentrations showed some degree of growth inhibition activity on T. vaginalis; however, hydroalcoholic extract was more efficient. https://greenmedinfo.com/article/all-extracts-and-oil-concentrations-showed-some-degree-growth-inhibition-activ PMID:  BMC Complement Med Ther. 2021 Oct 20 ;21(1):265. Epub 2021 Oct 20. PMID: 34670535 Abstract Title:  Antibacterial and anti-Trichomonas Vaginalis effects of Rosa Damascena mill petal oil (a persian medicine product), aqueous and hydroalcoholic extracts. Abstract:  BACKGROUND: Oils in traditional medicine are important products and used routinely for therapeutic purposes. Rose oil (Rosa damascene Mill), a product of Persian medicine, is advised for the treatment of Infectious diseases related to the female genitourinary tract. In the present study, R. damascena petal oil, aqueous, and hydroalcoholic extracts were evaluated for their in vitro antibacterial and anti-Trichomonas vaginalis effects.METHODS: Anti-trichomonas activity evaluation of extracts and oil were assayed by the Homocytometery method. Their antibacterial effects against Escherichia coli, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and clinically isolated Group B Streptococcus were assayed by broth microdilution in 96-well plates.RESULTS: The MIC of hydroalcoholic and aqueous extracts ranged from 25-50 and 25-100 mg/ml, respectively. Rose oil at all administered doses failed to show any antibacterial activity.CONCLUSION: All extracts and oil concentrations showed some degree of growth inhibition activity on T. vaginalis; however, hydroalcoholic extract was more efficient. <p><a href="https://greenmedinfo.com/article/all-extracts-and-oil-concentrations-showed-some-degree-growth-inhibition-activ" target="_blank">read more</a></p> https://greenmedinfo.com/article/all-extracts-and-oil-concentrations-showed-some-degree-growth-inhibition-activ#comments Escherichia coli Infections Pseudomonas aeruginosa Rose Staphylococcus aureus: Methicillin-resistant (MRSA) Streptococcus infections: Group B Trichomonas Infections Anti-Bacterial Agents Antiparasitic Agents In Vitro Study Mon, 08 Nov 2021 18:20:18 +0000 greenmedinfo 248523 at https://greenmedinfo.com Allicin extract exhibits anti-group B streptococci activity. https://greenmedinfo.com/article/allicin-extract-exhibits-anti-group-b-streptococci-activity PMID:  J Antimicrob Chemother. 2009 Jan;63(1):151-4. Epub 2008 Nov 11. PMID: 19001449 Abstract Title:  In vitro activity of an aqueous allicin extract and a novel allicin topical gel formulation against Lancefield group B streptococci. Abstract:  BACKGROUND: Studies have shown the efficacy of intra-partum antibiotics in preventing early-onset group B streptococcal sepsis. This approach results in a high intra-partum antibiotic use. Worryingly, the same antibiotics used in prophylaxis are also first-line treatment for neonatal sepsis, and antibiotic exposure in the peri-natal period has been shown to be a risk factor for late-onset serious bacterial infections and allergic disease. Antibiotic exposure in the peri-natal period is becoming a major public health issue; alternative strategies are needed. Garlic has been traditionally used to treat vaginal infections. Allicin is the main antibacterial agent isolated from garlic.OBJECTIVES: The aim of the study was to investigate the in vitro activity of a novel allicin extract in aqueous and gel formulation against 76 clinical isolates of Lancefield group B streptococci (GBS).METHODS: MICs and MBCs of allicin were determined for 76 GBS isolates by agar dilution and microtitre plate methods. Killing kinetics were determined for a selected 16 of the 76 strains. Agar diffusion tests were compared for allicin liquid and gel (500 mg/L).RESULTS AND CONCLUSIONS: MICs and MBCs of allicin liquid were 35 to 95 mg/L and 75 to 315 mg/L, respectively. Time/dose kill curves produced a 2-3 log reduction in cfu/mL within 3 h and no detectable growth at 8 and 24 h. A novel 500 mg/L allicin gel produced an average zone size of 23+/-6 mm compared with 21+/-6 mm for allicin in water. Aqueous allicin is bactericidal against GBS isolates and maintains activity in a novel gel formulation. https://greenmedinfo.com/article/allicin-extract-exhibits-anti-group-b-streptococci-activity#comments Allicin Garlic Streptococcus infections: Group B Anti-Bacterial Agents In Vitro Study Sat, 29 Jan 2011 21:34:24 +0000 greenmedinfo 60597 at https://greenmedinfo.com Although Group B streptococcus is one of the most important pathogens in neonatal infections, GBS-positive flora is associated with a lower risk of abnormality during pregnancy and abnormal pregnancy outcome compared with the GBS-negative flora. https://greenmedinfo.com/article/although-group-b-streptococcus-one-most-important-pathogens-neonatal-infection PMID:  Oncol Res. 1997;9(1):19-29. PMID: 12525892 Abstract Title:  Vaginal bacterial flora of pregnant women colonized with group B streptococcus. Abstract:  To elucidate the characteristics of group B streptococcus (GBS)-positive vaginal flora in pregnant women, vaginal cultures were conducted in 4025 women at 22 to 36 weeks of gestation. The results were analyzed by Fisher&#039;s exact test. Among 4025 women, 408 were found to be GBS positive and 3617 were GBS negative (GBS-negative group). A total of 1151 bacterial strains were recovered in the GBS-positive group and 6746 strains in the GBS-negative group. The percentages of Gram-positive cocci other than GBS, anaerobes, fungi, and Lactobacillus were 18.8%, 1.4%, 6.0%, and 34.4%, respectively, in the GBS-positive group, and 30.4%, 4.1%, 8.8%, and 53.5% in the GBS-negative group. The percentages were significantly lower in the GBS-positive group ( P &lt; 0.0001, P &lt; 0.0001, P= 0.0012, P &lt; 0.0001, respectively). Judging from the reduction in Lactobacillus, the GBS-positive vaginal flora is not considered a normal flora. However, it is not regarded as a pathogenic flora either, because the isolation rates of anaerobes (strongly associated with bacterial vaginosis) and fungi (occasionally causing vulvovaginal candidiasis) were lower than in the GBS-negative flora. These results suggest that the GBS-positive flora is associated with a lower risk of abnormality during pregnancy and abnormal pregnancy outcome compared with the GBS-negative flora, although this group is one of the most important pathogens in neonatal infections. https://greenmedinfo.com/article/although-group-b-streptococcus-one-most-important-pathogens-neonatal-infection#comments Neonatal Group B Streptococcal (GBS) Infections Streptococcus infections: Group B Review Sat, 09 May 2009 16:06:20 +0000 greenmedinfo 44089 at https://greenmedinfo.com Antibacterial and anti-biofilm activity of the human breast milk glycoprotein lactoferrin against group B Streptococcus. https://greenmedinfo.com/article/antibacterial-and-anti-biofilm-activity-human-breast-milk-glycoprotein-lactofe PMID:  Chembiochem. 2021 Mar 23. Epub 2021 Mar 23. PMID: 33755306 Abstract Title:  Antibacterial and Anti-biofilm Activity of the Human Breast Milk Glycoprotein Lactoferrin against Group B Streptococcus. Abstract:  Group B Streptococcus (GBS) is an encapsulated Gram-positive human pathogen that causes invasive infections in pregnant hosts and neonates, as well as immunocompromised individuals. Colonization of the human host requires the ability to adhere to mucosal surfaces and circumnavigate the nutritional challenges and antimicrobial defenses associated with the innate immune response. Biofilm formation is a critical process to facilitate GBS survival and establishment of a replicative niche in the vertebrate host. Previous work has shown that the host responds to GBS infection by producing the innate antimicrobial glycoprotein lactoferrin, which has been implicated in repressing bacterial growth and biofilm formation. Additionally, lactoferrin is highly abundant in human breast milk and could serve a protective role against invasive microbial pathogens. This study demonstrates that human breast milk lactoferrin has antimicrobial and anti-biofilm activity against GBS and inhibits its adherence to human gestational membranes. Together, these results indicate that human milk lactoferrin could be used as a prebiotic chemotherapeutic strategy to limit the impact of bacterial adherence and biofilm formation on GBS-associated disease outcomes. <p><a href="https://greenmedinfo.com/article/antibacterial-and-anti-biofilm-activity-human-breast-milk-glycoprotein-lactofe" target="_blank">read more</a></p> https://greenmedinfo.com/article/antibacterial-and-anti-biofilm-activity-human-breast-milk-glycoprotein-lactofe#comments Lactoferrin Streptococcus infections: Group B Anti-Bacterial Agents Bacterial Infections: Resistance/Biofilm Formation In Vitro Study Sun, 28 Mar 2021 22:21:38 +0000 greenmedinfo 237102 at https://greenmedinfo.com Breast Milk contain antimicrobial compounds. https://greenmedinfo.com/article/breast-milk-contain-antimicrobial-compounds PMID:  J Dairy Sci. 1992 Jun;75(6):1725-30. PMID: 1500569 Abstract Title:  Evaluation of postmilking teat germicides containing Lauricidin, saturated fatty acids, and lactic acid. Abstract:  The efficacies of postmilking teat germicides containing Lauricidin (glyceryl monolaurate), saturated fatty acids, lactic acid, and lauric acid were determined against new IMI caused by Staphylococcus aureus and Streptococcus agalactiae in three controlled infection trials. In trial 1, a germicide was evaluated containing 1% Lauricidin, 5% caprylic and capric acids, 6% lactic acid, and .85% lauric acid. New IMI with Staph. aureus and Strep. agalactiae were reduced 81.3 and 49.6%, respectively. Trial 2 germicide involved an artificially aged sample of the formulation evaluated in trial 1. The germicide was aged at 40 degrees C for 5 mo, which was approximately equal to 2 yr at room temperature (24 degrees C). Reductions in new IMI were 81.2 and 27.5% for Staph. aureus and Strep. agalactiae, respectively. In trial 3, a teat germicide aged at ambient temperature for 33 mo, which was originally formulated to contain 1% Lauricidin, 5% caprylic and capric acids, and 6% lactic acid, was evaluated. Reductions in new IMI were 75.5 and 40.4% for Staph. aureus and Strep. agalactiae, respectively. The formulation evaluated in trial 1 was superior to other formulations in reducing new IMI by the two test organisms. https://greenmedinfo.com/article/breast-milk-contain-antimicrobial-compounds#comments Breast Milk Lauric acid Staphylococcus aureus infection Streptococcus infections: Group B In Vitro Study Sat, 09 May 2009 16:22:05 +0000 greenmedinfo 44094 at https://greenmedinfo.com During pregnancy, vaginal administration of Lactobacillus rhamnosus BMX 54 is effective in preventing the development of abnormal vaginal microflora, lowering of the presenting part of the foetus and modifying cervical parameters that could represent risk https://greenmedinfo.com/article/during-pregnancy-vaginal-administration-lactobacillus-rhamnosus-bmx-54-effecti PMID:  Arch Gynecol Obstet. 2012 Mar 23. Epub 2012 Mar 23. PMID: 22437191 Abstract Title:  Normal vaginal flora, disorders and application of probiotics in pregnancy. Abstract:  PURPOSE: To assess the effectiveness of vaginal administration of the probiotic Lactobacillus rhamnosus BMX 54 in preventing the occurrence of abnormal vaginal flora and the alteration of parameters relevant to the progression of pregnancy. METHODS: Sixty pregnant women were assigned randomly to the untreated arm of the study (n = 30) or received (n = 30) vaginal application of one tablet containing Lactobacillus rhamnosus BMX 54, once a week for 12 weeks. Every 4 weeks (T0-T3), vaginal and cervical swabs were collected and pH, and quantity and quality of vaginal discharge measured as well as consistency, length anddilatation of cervix, and level of the presenting part of the foetus relative to interspinous diameter. RESULTS: In untreated women, there was a significant trend towards increase in the presence of pathogenic microorganisms in the vaginal and/or cervical swabs (p  https://greenmedinfo.com/article/during-pregnancy-vaginal-administration-lactobacillus-rhamnosus-bmx-54-effecti#comments Pregnancy: Descent of the Fetus' Head Pregnancy: Vaginal Flora Preterm Birth: Prevention Probiotics Streptococcus infections: Group B Human Study Tue, 03 Apr 2012 01:48:04 +0000 greenmedinfo 73878 at https://greenmedinfo.com Early Onset GBS Disease (EOGBSD) https://greenmedinfo.com/disease/early-onset-gbs-disease-eogbsd <div class="field field-image"> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_image" width="450" height="253" alt="" src="//cdn.greenmedinfo.com/sites/default/files/Streptococcus.jpg?1474412609" /> </div> </div> </div> <div class="field field-copyright"> <div class="field-items"> <div class="field-item odd"> Copyright: &lt;a href=&#039;http://www.123rf.com/profile_troscha&#039;&gt;troscha / 123RF Stock Photo&lt;/a&gt; </div> </div> </div> <fieldset class="fieldgroup group-facebook-like-info"><legend>Facebook Like Info</legend><div class="field field-facebook-total-count"> <div class="field-items"> <div class="field-item odd"> 0 </div> </div> </div> </fieldset> https://greenmedinfo.com/disease/early-onset-gbs-disease-eogbsd#comments Streptococcus infections: Group B Sat, 29 Jan 2011 21:39:58 +0000 greenmedinfo 60598 at https://greenmedinfo.com Early-onset neonatal group B streptococcal infections in New Zealand 1998-1999 were associated with young maternal age, parity, preterm labour, prolonged membrane rupture, maternal fever and assisted delivery as risk factors. Of the 56 cases, five (9%) w https://greenmedinfo.com/article/early-onset-neonatal-group-b-streptococcal-infections-new-zealand-1998-1999-we PMID:  J Paediatr Child Health. 2002 Jun;38(3):272-7. PMID: 12047696 Abstract Title:  Early-onset neonatal group B streptococcal infections in New Zealand 1998-1999. Abstract:  OBJECTIVE: To determine in New Zealand infants the attack rates, risk factors, preventive policies, strain serotype and antibiotic susceptibilities of early-onset neonatal group B streptococcus (GBS) infection.METHOD: A 2-year prospective active surveillance study was conducted in New Zealand&#039;s 19 neonatal units. Cases had to present within 48 h of delivery, be unwell, possess abnormal haematological indices and have GBS isolated from sterile sites.RESULTS: Of the 112 402 infants born in New Zealand during 1998-1999, 56 had early-onset GBS infection, an attack rate of 0.5 per 1000 live births (95% confidence interval [CI] 0.38, 0.65). Seven had meningitis and there was one death (case fatality rate of 1.8%; upper 95% CI 9.5%). Univariate analysis identified young maternal age, parity, preterm labour, prolonged membrane rupture, maternal fever and assisted delivery as risk factors. Preventive policies for GBS were reported by 14 (74%) obstetric centres associated with neonatal units. Of the 56 cases, five (9%) were born to mothers receiving intrapartum antibiotics, 32 (57%) had mothers with risk factors but were not treated with antibiotics, and 19 (34%) were born to mothers without identifiable risk factors for GBS prevention. Serotypes Ia and III predominated, while two isolates were resistant to erythromycin and/or clindamycin.CONCLUSIONS: Rates of early-onset GBS infection are similar to other countries following the introduction of prevention policies. Further reductions are possible with full implementation of these guidelines. Meanwhile, emergence of antibiotic resistance complicates the management of women with penicillin allergy. Vaccine development therefore remains a priority. https://greenmedinfo.com/article/early-onset-neonatal-group-b-streptococcal-infections-new-zealand-1998-1999-we#comments Neonatal group B stretpococcal (GBS) infections Streptococcus infections: Group B Anti-Bacterial Agents Intrapartum Antibiotics: Group B Streptococcus Meta Analysis Thu, 24 Mar 2011 03:44:05 +0000 greenmedinfo 62846 at https://greenmedinfo.com Evaluation of immune responses to group B Streptococcus type III oligosaccharides containing a minimal protective epitope. https://greenmedinfo.com/article/evaluation-immune-responses-group-b-streptococcus-type-iii-oligosaccharides-co PMID:  J Infect Dis. 2020 Mar 2 ;221(6):943-947. PMID: 31641758 Abstract Title:  Evaluation of Immune Responses to Group B Streptococcus Type III Oligosaccharides Containing a Minimal Protective Epitope. Abstract:  Recent structural studies demonstrated that the epitope recognized by a monoclonal antibody representative of the protective response against the type III group B Streptococcus polysaccharide was comprised within 2 of the repeating units that constitute the full-length native structure. In the current study, we took advantage of this discovery to design a novel vaccine based on multivalent presentation of the identified minimal epitope on a carrier protein. We show that highly glycosylated short oligosaccharide conjugates elicit functional immune responses comparable to those of the full-length native polysaccharide. The obtained results pave the way to the design of well-defined glycoconjugate vaccines based on short synthetic oligosaccharides. <p><a href="https://greenmedinfo.com/article/evaluation-immune-responses-group-b-streptococcus-type-iii-oligosaccharides-co" target="_blank">read more</a></p> https://greenmedinfo.com/article/evaluation-immune-responses-group-b-streptococcus-type-iii-oligosaccharides-co#comments Oligosaccharides Streptococcus infections: Group B Immunomodulatory In Vitro Study Thu, 16 Apr 2020 19:20:40 +0000 greenmedinfo 218680 at https://greenmedinfo.com Guts, Bugs and Babies https://greenmedinfo.com/blog/guts-bugs-and-babies <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2013<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="rtecenter" dir="ltr"><img alt="Like Mother, Like Child: How To Have A Healthy Pregnancy, Birth and Infant" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/Sayer Ji/images/like_mother_like_infant.jpg" style="height: 383px; width: 575px;" /></p> <p dir="ltr"><em><strong><span style="font-size: 0.9em;">The best part of my departure from conventional models of psychiatric care is that I no longer have to engage women in the Sophie's Choice between treatments that may be good for mom and not for baby or vice versa. &nbsp;Healthy medicine relies on interventions that benefit both mom and baby at once. &nbsp;</span></strong></em></p><p><a href="https://greenmedinfo.com/blog/guts-bugs-and-babies" target="_blank">read more</a></p> https://greenmedinfo.com/blog/guts-bugs-and-babies#comments Pregnancy Complications Prenatal Nutrition Streptococcus infections: Group B Cesarean Delivery Hospital Birth Infant and Children's Heatlh Intrapartum Antibiotics: All Intrapartum Antibiotics: Group B Streptococcus Natural Pregnancy Fri, 30 Aug 2013 00:54:29 +0000 drbrogan 109589 at https://greenmedinfo.com How to Treat a Vaginal Infection with a Clove of Garlic https://greenmedinfo.com/blog/how-treat-vaginal-infection-clove-garlic <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2023<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="beforesubhead rtecenter"><img alt="How To Treat A Yeast Infection With A Clove of Garlic" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/greenmedinfo/images/garlic_clove_infection.jpg" style="width: 400px; height: 340px;" title="How to Treat a Vaginal Infection with a Clove of Garlic" /></p> <p class="copyright">[Reprinted with the explicit permission of the author, J S Cohain. In-links added by GreenMedInfo.com. © 2003 Midwifery Today, Inc. All rights reserved.]</p> <p class="beforesubhead"><strong>by Judy Slome Cohain, CNM</strong></p> <p>Garlic kills yeast. Those who bake bread know not to add garlic while the dough is rising or it will kill the yeast. Instead, garlic is added to the dough after it has risen, just before baking it in the oven.</p><p><a href="https://greenmedinfo.com/blog/how-treat-vaginal-infection-clove-garlic" target="_blank">read more</a></p> https://greenmedinfo.com/blog/how-treat-vaginal-infection-clove-garlic#comments Allicin Garlic Neonatal Group B Streptococcal (GBS) Infections Neonatal group B stretpococcal (GBS) infections Streptococcus Infections Streptococcus infections: Group B Yeast Infection: Vaginal Intrapartum Antibiotics: Group B Streptococcus Natural Pregnancy Women's Health garlic for vaginal infection How to Treat a Vaginal Infection How to Treat a Vaginal Infection with a Clove of Garlic treat vaginal infection treat vaginal infection naturally Fri, 24 Feb 2023 15:03:43 +0000 judyslome 76349 at https://greenmedinfo.com Lactobacilli rhamnosus and related strains may offer a safe and inexpensive alternative in the treatment of group B streptococci. https://greenmedinfo.com/article/lactobacilli-rhamnosus-and-related-strains-may-offer-safe-and-inexpensive-alte PMID:  Mikrobiyol Bul. 2005 Jan;39(1):17-23. PMID: 15900833 Abstract Title:  [Inhibitor effect of vaginal lactobacilli on group B streptococci]. Abstract:  Neonatal group B streptococcal (GBS) infections are one of the important health problems because of their high mortality and morbidity rates in certain countries. There are some preventive approaches, including perinatal antibiotic therapy against these infections. Recently, vaccination with conjugated GBS polysaccharides has also been practised. In this study, the in vitro inhibitory effects of 51 lactobacilli (of them 50 were purified from vaginal swabs, 1 from a commercial vaginal tablet) on five GBS (4 clinical isolates and 1 standard strain) were investigated by sandwich plate technique and deferred antagonism well technique. Ten clinical isolates (20%) and the drug-purified Lactobacilli expressed pronounced inhibitory effects on growth of GBS. All of the inhibitory isolates and 10 randomly selected non-inhibitory isolates were identified by API 50CHL kit (BioMeriéx, France). Seven (70%) of the inhibitory clinical isolates were Lactobacillus rhamnosus. The inhibitory isolates had higher acid production than the non-inhibitory ones (p &lt; 0.05), and pH-adjustment destroyed their inhibitory effects entirely. If these results could be applied in vivo, it could be postulated that administration of certain lactobacilli as probiotics via an appropriate regimen may be a safe, physiological and cheaper alternative for prevention of neonatal GBS infections. https://greenmedinfo.com/article/lactobacilli-rhamnosus-and-related-strains-may-offer-safe-and-inexpensive-alte#comments Lactobacillus rhamnosus GG Streptococcus infections: Group B Human Study Mon, 20 Apr 2009 06:10:20 +0000 greenmedinfo 41780 at https://greenmedinfo.com Lactobacillus rhamnosus reduces the cytotoxic effects of group B streptococcus on HeLa cells. https://greenmedinfo.com/article/lactobacillus-rhamnosus-reduces-cytotoxic-effects-group-b-streptococcus-hela-c PMID:  Microb Pathog. 2021 Dec ;161(Pt A):105271. Epub 2021 Oct 30. PMID: 34728370 Abstract Title:  Lactobacillus rhamnosus reduces the cytotoxic effects of group B streptococcus on HeLa cells. Abstract:  Group B Streptococcus (GBS) is an opportunistic pathogen found in the vaginal tract and is a leading cause of preterm birth and neonatal illness. Aside from GBS, the vaginal tract is predominantly colonized by commensal Lactobacillus species that are thought to protect the vaginal tract from pathogens, including GBS. Studies that examined if, and how Lactobacilli modulate GBS pathogenicity remain limited. This study sought to investigate the potential protective role of Lactobacillus rhamnosus against GBS, using an in vitro model system. Immunofluorescence microscopy and Scanning Electron Microscopy (SEM) captured images of infected HeLa cells and were analyzed using the image analysis program ImageJ. Results indicate that GBS causes HeLa cell detachment unless L. rhamnosus is present. SEM images show that GBS reduces length and number of microvilli on HeLa cell surface, as well as size of secreted vesicles. L. rhamnosus partially inhibits GBS-dependent microvilli and vesicle disruption. GBS also disrupts HeLa cell F-actin fibers unless L. rhamnosus is present. These results reveal effects of GBS infection on the host cell cytoskeleton and implies a protective role of L. rhamnosus against GBS colonization. <p><a href="https://greenmedinfo.com/article/lactobacillus-rhamnosus-reduces-cytotoxic-effects-group-b-streptococcus-hela-c" target="_blank">read more</a></p> https://greenmedinfo.com/article/lactobacillus-rhamnosus-reduces-cytotoxic-effects-group-b-streptococcus-hela-c#comments Lactobacillus rhamnosus Streptococcus infections: Group B Anti-Bacterial Agents In Vitro Study Sat, 01 Jan 2022 18:55:16 +0000 greenmedinfo 251069 at https://greenmedinfo.com Late onset Serious Bacterial Infections exhibiting antibiotic-resistance are more likely to occur to infants who received intrapartum antibiotics. https://greenmedinfo.com/article/late-onset-serious-bacterial-infections-exhibiting-antibiotic-resistance-are-m PMID:  Pediatrics. 2005 Sep;116(3):696-702. PMID: 16140710 Abstract Title:  Association of intrapartum antibiotic exposure and late-onset serious bacterial infections in infants. Abstract:  OBJECTIVE: Recommendations to prevent vertical transmission of group B Streptococcus (GBS) infections have resulted in many women&#039;s receiving antibiotics during labor with an associated reduction in early-onset GBS infections in their newborn infants. However, a potential relationship of intrapartum antibiotics (IPA) to the occurrence of late-onset (7-90 days) serious bacterial infections (SBIs) in term infants has not been reported. The objectives of this study were to determine whether infants with late-onset SBI were more likely than healthy control infants to have been exposed to IPA and whether there was a greater likelihood of antibiotic resistance in bacteria that were isolated from infants who had an SBI and had been exposed to IPA compared with those who had not. METHODS: We used a case-control design to study the first objective. Cases were previously healthy full-term infants who were hospitalized for late-onset SBI between the ages of 7 and 90 days. Control subjects were healthy full-term infants who were known not to have an SBI in their first 90 days. Cases and control subjects were matched for hospital of delivery. In the second part of the study, rates of antibiotic resistance of bacteria that were isolated from infected infants were compared for those who had and had not been exposed to IPA. RESULTS: Ninety case infants and 92 control subjects were studied. Considering all types of IPA, more case (41%) than control infants (27%) had been exposed to IPA (adjusted odds ratio [OR]: 1.96; 95% confidence interval [CI]: 1.05-3.66), after controlling for hospital of delivery. The association was stronger when IPA was with broad-spectrum antibiotics (adjusted OR: 4.95; 95% CI: 2.04-11.98), after controlling for hospital of delivery, penicillin IPA, maternal chorioamnionitis, and breastfeeding. Bacteria that were isolated from infected infants who had been exposed to IPA were more likely to exhibit ampicillin resistance (adjusted OR: 5.7; 95% CI: 2.3-14.3), after controlling for hospital of delivery, but not to other antibiotics that are commonly used to treat SBI in infants. CONCLUSIONS: After adjusting for potential confounders, infants with late-onset SBI were more likely to have been exposed to IPA than noninfected control infants. Pathogens that cause late-onset SBI were more likely to be resistant to ampicillin when the infant had been exposed to intrapartum antibiotics. https://greenmedinfo.com/article/late-onset-serious-bacterial-infections-exhibiting-antibiotic-resistance-are-m#comments Neonatal Group B Streptococcal (GBS) Infections Streptococcus infections: Group B Intrapartum Antibiotics: Group B Streptococcus Human Study Sat, 09 May 2009 16:16:19 +0000 greenmedinfo 44091 at https://greenmedinfo.com